Guiding Dose Increases in Patients Incompletely Responsive to Usual Doses of Atomoxetine

Clinical trial NCT00485407 · COMPLETED

Trial details

NCT number: NCT00485407
Sponsor: Eli Lilly and Company
Status: COMPLETED
Phase: Phase 3
Study type: INTERVENTIONAL

Attention Deficit Hyperactivity Disorder

Start date: 2003-07-01
Enrollment: 377

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.